Abstracts tagged "Cutaneous manifestations"

Abstract Number: 246 • 2019 ACR/ARP Annual Meeting
Smoking Exposure in Pack-Years Predicts Cutaneous Manifestations of Lupus
Nnenna Ezeh¹, Trevor McKown ¹, Shivani Garg ¹ and Christie Bartels ¹, ¹University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Patients of color are more likely to have systemic lupus erythematosus (SLE) and a smoking history. Prior literature notes that both smoking and race…
Abstract Number: 2977 • 2018 ACR/ARHP Annual Meeting
Lenabasum, a Cannabinoid Type 2 Receptor Agonist, Reduces T-Cell Population and Downregulates Type 1 and 2 Interferon Activities in Lesional Dermatomyositis Skin
Nithin Reddy^1,2, Majid Zeidi^1,2, Barbara White³ and Victoria P. Werth^1,2, ¹University of Pennsylvania, Philadelphia, PA, ²Philadelphia Veterans Affairs Medical Center, Philadelphia, PA, ³Corbus Pharmaceuticals, Inc., Norwood, MA
Background/Purpose: Lenabasum is a synthetic, non-immunosuppressive, selective cannabinoid receptor type 2 (CB2) agonist that activates resolution of innate immune responses. CB2 is a G-protein coupled…
Abstract Number: 465 • 2018 ACR/ARHP Annual Meeting
Seasonal Variation in Cutaneous Flares for Pediatric Lupus
Tamara Tanner¹, Marija Dionizovik-Dimanovski², Dawn Wahezi³ and Tamar Rubinstein³, ¹Albert Einstein College of Medicine/ Children's Hospital at Montefiore, Albert Einstein College of Medicine/ Children's Hospital at Montefiore, Bronx, NY, ²Pediatric Rheumatology, Children's Hospital at Montefiore, Bronx, NY, ³Pediatric Rheumatology, Albert Einstein College of Medicine, Children's Hospital at Montefiore, Bronx, NY
Background/Purpose: Exposure to sunlight has been proposed as a possible environmental trigger for lupus flares, particularly cutaneous disease. Contradictory findings exist regarding seasonal variation in…
Abstract Number: 2284 • 2018 ACR/ARHP Annual Meeting
Safety and Efficacy of Lenabasum in Refractory Skin-Predominant Dermatomyositis Subjects Treated on an Open-Label Extension of Trial JBT101-DM-001
Victoria P. Werth^1,2, David Pearson^1,2, Joyce Okawa^1,2, Rui Feng³, Josef Concha^1,2, Basil Patel^1,2, Emily Hejazi^1,2, Caitlin Cornwall⁴, Scott Constantine⁴ and Barbara White⁴, ¹University of Pennsylvania, Philadelphia, PA, ²Philadelphia Veterans Affairs Medical Center, Philadelphia, PA, ³University of Pennsylvania, Philadelphia', PA, ⁴Corbus Pharmaceuticals, Inc., Norwood, MA
Background/Purpose: Lenabasum is a synthetic, non-immunosuppressive, selective cannabinoid receptor type 2 agonist that activates resolution of innate immune responses. Lenabasum had acceptable safety and tolerability…
Abstract Number: 2287 • 2018 ACR/ARHP Annual Meeting
Interim Results of an Open-Label Study Assessing Efficacy and Safety of Adrenocorticotropic Hormone Gel for Treatment of Refractory Cutaneous Manifestations of Dermatomyositis
Anthony Fernandez, Dermatology and Pathology, Cleveland Clinic, Cleveland, OH
Background/Purpose: Cutaneous dermatomyositis (DM) is often refractory to multiple medications, suggesting better treatments are needed. Adrenocorticotropic hormone gel is a repository corticotropin injection that is…
Abstract Number: 2853 • 2018 ACR/ARHP Annual Meeting
A Protective Langerhans Cell-Keratinocyte Axis That Is Dysfunctional in Photosensitivity
William D. Shipman^1,2,3, Susan Chyou¹, Anusha Ramanathan¹, Peter M. Izmirly⁴, Sneh Sharma⁵, Tania Pannellini⁶, Dragos Dasoveanu¹, Xiaoping Qing⁷, Cynthia Magro⁸, Richard Granstein⁹, Michelle Lowes¹⁰, Eric Pamer¹¹, Daniel Kaplan¹², Jane E. Salmon^13,14, Babak Mehrara¹⁵, James Young^10,11,16,17, Robert M. Clancy¹⁸, Carl Blobel^14,19,20 and Theresa T. Lu^2,3,21, ¹Autoimmunity and Inflammation Program, Hospital for Special Surgery, New York, NY, ²Immunology and Microbial Pathogenesis Program, Weill Cornell Graduate School of Medical Sciences, New York, NY, ³Weill Cornell/Rockefeller/Sloan Kettering Tri-Institutional MD-PhD Program, New York, NY, ⁴Rheumatology, NYU School of Medicine, New York, NY, ⁵Laboratory of Cellular Immunobiology, Memorial Sloan Kettering Cancer Center, New York, NY, ⁶Hospital for Special Surgery, New York, NY, ⁷Program in Inflammation and Autoimmunity, Hospital for Special Surgery, New York, NY, ⁸Pathology, Weill Cornell Medicine, New York, NY, ⁹Dermatology, Weill Cornell Medicine, New York, NY, ¹⁰Rockefeller University, New York, NY, ¹¹Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, ¹²Immunology, University of Pittsburgh, New, NY, ¹³Medicine/Rheumatology, Hospital for Special Surgery, New York, NY, ¹⁴Weill Cornell Medicine, New York, NY, ¹⁵Plastic Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, ¹⁶Immunology, Memorial Sloan Kettering Cancer Center, New York, NY, ¹⁷Medicine, Weill Cornell Medicine, New York, NY, ¹⁸Department of Medicine, Division of Rheumatology, NYU School of Medicine, New York, NY, ¹⁹Arthritis and Tissue Degeneration Program, Hospital for Special Surgery, New York, NY, ²⁰Institute of Advanced Studies, Technical University of Munich, New York, NY, ²¹Autoimmunity and Inflammation Program and Pediatric Rheumatology, Hospital for Special Surgery, New York, NY
Background/Purpose: Photosensitivity, or skin sensitivity to ultraviolet radiation (UVR), is a feature of lupus erythematosus (LE) and other autoimmune conditions. Photosensitive lesions can be disfiguring…
Abstract Number: 2156 • 2017 ACR/ARHP Annual Meeting
Comparison of Patients with Dermatomyositis in a Specialty Clinic Versus Clinical Trial with Anabasum (JBT-101), a Cannabinoid Receptor Type 2 Agonist
Victoria P Werth¹, Emily Hejazi², Sandra M. Pena³, Jessica S. Haber⁴, Joyce Okawa³, Rui Feng⁵, Kirubel Gabre², Josef Concha², Scott Constantine⁶ and Barbara White⁶, ¹University of Pennsylvania and the VA Medical Center, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁴Department of Dermatology, University of Pennsylvania, Philadelphia, PA, ⁵Department of Biostatistics and Epidemiology at the Hospital of the University of Pennsylvania, Philadelphia, PA, ⁶Corbus Pharmaceuticals, Inc., Norwood, MA
Background/Purpose: There are limited treatment options and no published double-blind randomized placebo-controlled trials for the treatment of skin manifestations of dermatomyositis (DM). There is no…
Abstract Number: 2157 • 2017 ACR/ARHP Annual Meeting
Factors Associated with Clinical Remission of Skin Disease in Dermatomyositis
Paige Wolstencroft¹, Lorinda Chung², Shufeng Li¹, Livia Casciola-Rosen³ and David Fiorentino⁴, ¹Dermatology, Stanford University School of Medicine, Stanford, CA, ²Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ³Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Department of Dermatology, Stanford University School of Medicine, Palo Alto, CA
Background/Purpose: Quantitative estimates of the duration and severity of cutaneous disease are lacking for adult dermatomyositis (DM) patients. The Cutaneous Dermatomyositis Disease Area and Severity…
Abstract Number: 2749 • 2017 ACR/ARHP Annual Meeting
Four-Distinct Phenotypes of Patients with Necrotizing Arteritis of Medium and Small Arteries
Tsuyoshi Shirai¹, Hiroshi Fujii¹, Yoko Fujita², Yuko Shirota¹, Tomonori Ishii¹ and Hideo Harigae¹, ¹Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan, ²Department of Hematolgy and Rheumatolgy, Tohoku University Graduate School of Medicine, Sendai, Japan
Background/Purpose: Polyarteritis nodosa (PAN) is a necrotizing arteritis of medium and small arteries. PAN is divided into systemic and cutaneous PAN (cPAN). cPAN can be…
Abstract Number: 1186 • 2016 ACR/ARHP Annual Meeting
The Use of Clinical Mucosal Manifestations to Differentiate Patients with Lupus and Dermatomyositis: Transversal, Retrospective and Analytical Study of 116 Patients
Cristián Vera-Kellet Sr., Pablo del Barrio-Díaz Sr., Jorge Manríquez-Moreno Sr. and Carlos Reyes-Vivanco Sr., Dermatology, Pontificia Universidad Católica de Chile, Santiago, Chile
Background/Purpose: There are few studies comparing oral manifestations in patients with Cutaneous Lupus (CL), Systemic Lupus Erythematosus (SLE) and Dermatomyositis (DM). Our objective was to…
Abstract Number: 1949 • 2016 ACR/ARHP Annual Meeting
Presentation, Prognosis and Clinical-Pathological Correlations of Cutaneous Manifestations in ANCA-Associated Vasculitides
Laure Frumholtz¹, Sara Laurent², Olivier Aumaître³, Francois Maurier⁴, Guillaume Le Guenno⁵, Agnès Carlotti², Alexiane Dallot², Jean-Louis Kemeny⁶, Laurent Antunes⁷, Nicolas Froment⁷, Sylvie Fraitag⁸, Jonathan London⁹, Claire Le Jeunne¹⁰, Benoit Terris², Luc Mouthon¹⁰, Selim Aractingi¹¹, Loïc Guillevin¹⁰, Nicolas Dupin¹¹ and Benjamin Terrier¹², ¹Internal Medicine, Cochin Hospital, Paris, France, ²Pathology, Cochin Hospital, Paris, France, ³CHU Pitié-Salpêtrière - Department of Internal Medicine 2. Referal center for SLE/APS, Paris, France, ⁴Department of Internal Medicine, HP Metz Belle Isle Hospital, Metz, France, ⁵Internal Medicine department, Clermont-Ferrand, France, ⁶Pathology, CHU, Clermont-Ferrand, France, ⁷Pathology, CH, Metz, France, ⁸Pathology, Necker, Paris, France, ⁹INSERM U1016, Institut Cochin, Equipe Neutrophiles et Vascularites, Paris, France, ¹⁰Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France, ¹¹Dermatology, Cochin Hospital, Paris, France, ¹²National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France
Background/Purpose: Cutaneous involvement is frequent during ANCA-associated vasculitis (AAV) and can reveal the disease. However, no large study on presentation and clinical-pathological correlations is available.…
Abstract Number: 2969 • 2016 ACR/ARHP Annual Meeting
10 Year Retrospective Analysis of 276 Cases of Histopathologically Confirmed Leukocytoclastic Vasculitis
Shazdeh Butt¹ and Thomas Olenginski², ¹Rheumatology, Geisinger Medical Center, Danville, PA, ²Department of Rheumatology, Geisinger Medical Center, Danville, PA
Background/Purpose: We identified leukocytoclastic vasculitis (LCV) patients seen over 10 years at our institution. Aims included 1) define cause; 2) record lab, imaging, and ancillary…
Abstract Number: 62 • 2015 ACR/ARHP Annual Meeting
Patient Perception of Disease Burden in Diffuse Cutaneous Systemic Sclerosis
Dinesh Khanna¹, Yannick Allanore², Christopher P. Denton³, Marco Matucci-Cerinic⁴, Janet E. Pope⁵, Barbara Hinzmann⁶, Siobhan Briody⁷, Janethe de Oliveira Pena⁸ and Oliver Distler⁹, ¹Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²Immunogenetics, Cochin Institute, Paris, France, ³Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom, ⁴Department of Medicine, Division of Rheumatology, University of Florence, Florence, Italy, ⁵University of Western Ontario, London, ON, Canada, ⁶Bayer Pharma AG, Berlin, Germany, ⁷Blueprint Partnership, Manchester, United Kingdom, ⁸Bayer HealthCare Pharma, Whippany, NJ, ⁹Research of Systemic Autoimmune Diseases, Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland
Background/Purpose: Diffuse cutaneous SSc (dcSSc) is associated with high morbidity and mortality, and reduced quality of life. Patient priorities are rarely discussed, with physicians traditionally…
Abstract Number: 425 • 2015 ACR/ARHP Annual Meeting
Impact of in Utero Hydroxychloroquine Exposure on Age of Onset of Cutaneous Neonatal Lupus
Julie Barsalou¹, Nathalie Costedoat-Chalumeau², Cesar Fors-Nieves³, Ummara Shah⁴, Patrick Brown⁵, Carl Laskin⁶, Nathalie Morel², Kateri Levesque⁷, Jill P. Buyon⁸, Earl Silverman⁹ and Peter M. Izmirly¹⁰, ¹Pediatric Rheumatology, CHU Sainte-Justine, Université de Montréal, Montréal, QC, Canada, ²Internal Medicine Department, Cochin Hospital, “René-Descartes Paris V” University, Paris, France, ³Division of Rheumatology, NYU School of Medicine, New York, NY, ⁴Medicine, Strong Memorial Hospital, University of Rochester, Rochester, NY, ⁵University of Toronto, Toronto, ON, Canada, ⁶Medicine, Rheumatology and Obstetrics and Gynecology, University of Toronto and LifeQuest Centre for Reproductive Medicine, Toronto, ON, Canada, ⁷Internal Medicine, CHU Ste-Justine, Montréal, QC, Canada, ⁸NYU School of Medicine, New York, NY, ⁹Division of Rheumatology, Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, ¹⁰Rheumatology, NYU School of Medicine, New York, NY
Background/Purpose: Biopsy specimens of cutaneous neonatal lupus (cNL) lesions usually show interface dermatitis. Hydroxychloroquine (HCQ) is an effective treatment for interface dermatitis seen in connective…
Abstract Number: 1074 • 2015 ACR/ARHP Annual Meeting
DNA Methylation Patterns in Naïve CD4+ T Cells Identify Epigenetic Susceptibility Loci for Malar Rash and Discoid Rash in Systemic Lupus Erythematosus
Paul Renauer¹, Patrick Coit¹, Matlock A. Jeffries², Joan T. Merrill³, W Joseph McCune⁴, Kathleen Maksimowicz-McKinnon⁵ and Amr H. Sawalha⁶, ¹Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²Rheumatology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Int Med/ Rheum, University of Michigan, Ann Arbor, MI, ⁵Rheumatology, Henry Ford Hospital, Detroit, MI, ⁶Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterized by heterogeneous clinical manifestations, autoantibody production, and epigenetic dysregulation in T cells. We sought…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].